Other Mutations: SMARCB1

NCT05355753: A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

NCT05355753
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: SMARCB1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 16 Years and older (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients without at least 1 prior line of standard-of-care systemic therapy; Patients with symptomatic, unstable, untreated brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT05355753

NCT03739827: Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

NCT03739827
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: SMARCA4, SMARCB1
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: Must be a patient at Cedars-Sinai Medical Center
Exclusions: 
https://ClinicalTrials.gov/show/NCT03739827

Up ↑